<DOC>
	<DOCNO>NCT00388882</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety 12 week treatment tiotro pium HandiHaler® 18 mcg daily compare Combivent® MDI CFC Inhalation Aerosol 2 actuation qid COPD patient currently prescribe Combivent® MDI .</brief_summary>
	<brief_title>Trial Comparing Treatment With Tiotropium Inhalation Capsules Combivent® Inhalation Aerosol COPD Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Diagnosis COPD Age : &gt; = 40 year Current exsmoker &gt; = 10 packyear smoke history Use Combivent® MDI &gt; = 1 month prior Visit 1 Spirometric criterion ( determine study visit ) : Postbronchodilator FEV1 &lt; = 70 % ( Visit 1 ) Prebronchodilator FEV1 &lt; = 65 % predict FEV1/FVC &lt; = 70 % ( Visit 2 ) Clinical history asthma History thoracotomy pulmonary resection History CF , alpha 1 antitrypsin deficiency interstitial lung disease Daytime use oxygen therapy &gt; 1 hour per day unable abstain use oxygen PFTs Any respiratory tract infection COPD exacerbation 6 week prior Visit 1 Recent history 6 month less MI Unstable lifethreatening cardiac arrhythmias Hospitalization CHF past year Malignancy patient receive chemo radiation therapy Pregnant nursing woman Known hypersensitivity ipratropium carrier substance , include relate food product soybean , peanut , lactose Use SPIRIVA® 3 month prior Visit 1 Symptomatic prostatic hypertrophy bladder neck obstruction Known narrow angle glaucoma Participating pulmonary rehab program within 4 week Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>